Want to see KR:092730 full AI Analyst Report?
NeoPharm Co., Ltd. (092730) Financial Statements
NeoPharm Co., Ltd. Financial Overview
NeoPharm Co., Ltd.'s market cap is currently $348.02B. The company's EPS TTM is $1873.90; its P/E ratio is 6.12; and it has a dividend yield of 5.34%. NeoPharm Co., Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 132.18B | $ 119.01B | $ 97.10B | $ 85.03B | $ 87.93B |
| Gross Profit | $ 84.71B | $ 74.03B | $ 65.39B | $ 58.38B | $ 62.39B |
| Operating Income | $ 28.77B | $ 24.65B | $ 25.31B | $ 21.44B | $ 22.43B |
| EBITDA | $ 31.88B | $ 33.40B | $ 31.01B | $ 24.95B | $ 25.37B |
| Net Income | $ 27.82B | $ 23.06B | $ 23.21B | $ 17.03B | $ 17.71B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 141.74B | $ 126.52B | $ 111.99B | $ 113.49B | $ 105.05B |
| Total Assets | $ 220.28B | $ 192.44B | $ 177.46B | $ 155.35B | $ 143.41B |
| Total Debt | $ 1.92B | $ 629.40M | $ 1.07B | $ 412.16M | $ 558.77M |
| Net Debt | $ -24.91B | $ -17.60B | $ -10.82B | $ -10.47B | $ -6.49B |
| Total Liabilities | $ 24.92B | $ 15.56B | $ 17.43B | $ 13.14B | $ 13.10B |
| Stockholders' Equity | $ 195.36B | $ 176.88B | $ 160.03B | $ 142.21B | $ 130.30B |
| Cash Flow | |||||
| Free Cash Flow | $ 27.23B | $ 15.55B | $ 2.43B | $ 17.35B | $ 21.20B |
| Operating Cash Flow | $ 28.41B | $ 18.63B | $ 23.26B | $ 18.16B | $ 21.68B |
| Investing Cash Flow | $ -9.60B | $ -6.22B | $ -16.35B | $ -8.80B | $ -16.69B |
| Financing Cash Flow | $ -10.18B | $ -6.50B | $ -5.92B | $ -5.75B | $ -9.52B |
Currency in KRW